Research Guide

Precision Treatment Becomes a New Trend Mr. Jiang’s case is a microcosm of the Department of Cardiology at Shulan Hospital exploring precision treatment for cardiovascular diseases. In recent years, with the development of medical technology, the treatment of cardiovascular diseases has evolved from traditional "symptomatic treatment" to the "targeted treatment era," bringing new hope to more patients.

"Currently, our team is capable of performing almost all the world’s most advanced cardiovascular interventional diagnosis and treatment technologies, striving to provide comprehensive treatment guarantees for patients with various high-risk, difficult, and complex cardiovascular diseases," said Fu Guosheng.

Minimally invasive surgery For Lung Cancer has achieved major breakthroughs. Assisted by thoracoscopy, it only requires a small incision of 3 cm. It reduces the need for blood transfusion—95% of patients do not require transfusion. The operation time is shortened to within 2 hours, and the hospital stay is reduced from two weeks to one week. It improves the radicality of the surgery, increasing the 5-year survival rate by 6% and significantly enhancing the quality of life.

In the "battlefield" of cancer treatment, radiotherapy and chemotherapy are two core "weapons" commonly used by doctors. However, many patients and their families often confuse the two: "Both treat cancer—what’s the real difference between radiotherapy and chemotherapy?" "Which treatment is more suitable for me?" Today, we will fully break down these two treatment methods, helping you understand their core differences, applicable scenarios, and key considerations.

Malignant tumors are one of the major diseases seriously threatening human health and life, Based on existing evidence-based medical evidence, combined with domestic and international guidelines and consensuses, the Chinese Anti-Cancer Association (CACA) has formulated these Guidelines for the Clinical Application of Malignant Tumor Immunotherapy Technologies, aiming to provide assistance to clinicians engaged in clinical immunotherapy.

At the 2025 American Society of Hematology (ASH) Annual Meeting, Senior journalist Peter Goodwin from Audio Journal of Oncology invited Professor Du Juan from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine for an on-site interview regarding her team’s research: "FasTCAR-T (GC012F/AZD0120) targeting both BCMA and CD19 as a first-line treatment for newly diagnosed multiple myeloma (NDMM)."

After Varian launched HyperSight and it was implemented clinically, how did opinions from the frontlines change? If you ask a radiologist: "Can I use HyperSight to replace the department’s 256-slice CT for hospital-wide cardiac coronary angiography screening?" Answer: No need. Physical structure dictates high-end spiral CT’s dominance in ultimate SNR. However, in the context of tumor diagnosis, this gap is clinically imperceptible.

Understand the Truth About Gynecomastia Many patients initially think they simply have fat on their chests. They try fitness and dieting but find that the "fat lumps" persist stubbornly. In fact, gynecomastia is caused by benign hyperplasia of mammary glands or adipose tissue, while simple obesity (pseudo-gynecomastia) is due to fat accumulation.

Novel cell therapy shows potential: As an emerging cellular immunotherapy method, CAR-NK cell therapy can still be effective in patients who have failed CAR-T treatment. With mild CRS (cytokine release syndrome) reaction and good safety, it provides a new treatment option for refractory and relapsed patients and is expected to become an important treatment direction for such patients in the future;

Multiple Myeloma (MM) is the second most common hematological malignancy worldwide and the third most common in China. It originates from plasma cells in the bone marrow, which are "immune warriors" that normally synthesize antibodies to fight infection. When these cells become malignant, they proliferate uncontrollably, crowding out healthy cells and destroying bone and kidney functions. Due to its insidious onset and diverse symptoms, the misdiagnosis rate is as high as 50%

Minimally Invasive Cardiovascular Surgery (MICS) is one of the fastest-developing subspecialties in cardiovascular surgery. Due to less trauma, fewer complications, and faster recovery, MICS is a key development direction. The China National Minimally Invasive Cardiovascular Surgery Professional Committee (CMICS) promotes aligning domestic techniques with international standards. The goal is to summarize MICS progress in China, its clinical effects, and future trends.

On September 25, the research team led by Shen Zhongyang and Wang Shusen from Tianjin First Central Hospital, together with Deng Hongkui's team from Peking University/Changping Laboratory, published a landmark paper in the top journal Cell. For the first time globally, they achieved clinical functional cure of type 1 diabetes through innovative stem cell-derived islet transplantation. The patient no longer required exogenous insulin therapy during the 1-year follow-up period.

Driven by continued Chinese innovation, robust market demand, and industrial upgrades, the DBS industry is poised for a significant development period. It is expected that China will play an increasingly pivotal role in the field of neuro-modulation, offering more "Chinese Solutions" to global neurological disorder patients in the years to come.

Early-stage, radiation-sensitive tumors: Curative radiation (goal: cure). · Need to shrink tumors preoperatively or eliminate residuals postoperatively: Adjuvant radiation (goal: prevent recurrence). · Advanced cancer with severe pain, bleeding, or compression: Palliative radiation (goal: reduce suffering). Radiation therapy is personalized. Consult doctors/medical physicists for tailored plans to avoid detours.

A turning point came after the 2024 Spring Festival—Awen sought help from the transplant team led by Director Wu Tong and Director Song Yanzhi at Beijing GoBroad Boren Hospital. Under the treatment of the expert team, she first received chemotherapy combined with targeted therapy, followed by a second HSCT. Today, more than a year has passed since the second transplantation. Awen returns to the hospital for regular re-examinations, her condition is stable, and her body is gra

China has established a robust clinical research framework for thalassemia gene therapy through collaboration among leading medical centers and biotech companies. With the accumulation of positive clinical data and optimization of protocols, gene therapy is poised to offer a potential functional cure for many thalassemia patients, demonstrating China's growing capability and potential in the global advanced therapy landscape.

Unlike traditional radiotherapy, which employs X-rays or gamma rays, proton beams exhibit a unique energy deposition pattern in matter. They deliver a lower dose as they enter the body and release most of their energy at a specific depth, known as the Bragg Peak. This Bragg Peak effect allows proton therapy to precisely concentrate a higher radiation dose on the tumor while minimizing damage to surrounding healthy tissues, achieving targeted "precision bombing" to cancer cell

The field of diabetes cell and gene therapy exhibits a development landscape where the United States and China possess distinct advantages: 1. The United States maintains leadership in original technology. 2. China holds advantages in the speed of clinical translation and patient resources. 3. International cooperation and complementarity are key for the future.

Hematopoietic Stem Cell Transplantation (HSCT) is an effective treatment for malignant hematological tumors. One of the key factors determining the success of HSCT is Human Leukocyte Antigen (HLA) matching. If the HLA of the donor and the patient (recipient) do not match, severe rejection may occur, even endangering life.

Thalassemia is an inherited hemolytic anemia caused by globin gene defects. First discovered along the Mediterranean coast, it derives its name from this region. Its core characteristic is impaired hemoglobin (Hb) synthesis due to globin gene mutations, leading to ineffective erythropoiesis and ultimately chronic anemia of varying severity.